Under the agreement, Wyeth will continue to apply Affymetrix technology in numerous areas of the drug discovery and development process.
Wyeth will continue to use Affymetrix microarray technology to identify new drug targets and gain a better understanding of the genetic markers that potentially correlate with a patient's response to therapy. The latest GeneChip technology enables them to more accurately classify disease, predict clinical progression and determine likelihoods of treatment success.
“We anticipate that a better understanding of human genetic variations and the ability to look at the entire genome in greater detail will dramatically accelerate research and, ultimately, help bring more effective tests and therapies to market faster,” said Chip Leveille, vice president of the pharmaceutical business unit at Affymetrix.